VENUE: Eva and Georg Klein Lecture Hall, Biomedicum, KI

08.30 – REGISTRATION OPENS (COFFEE)

09.00 - 9.30 SCNP GENERAL ASSEMBLY (MEMBERS ONLY)

09:30 – 9.45 SCNP PRESIDENTS’ WELCOME TO SCNP 61^ST ANNUAL MEETING

• Sophie Erhardt, Professor, Karolinska Institutet, Sweden

09.45 – 10.30 SCNP 2020 OPENING LECTURE

Moderator: Carl Björkholm, PhD, Janssen Pharmaceuticals, Sweden

Speaker: Future therapies for Alzheimer’s disease

• Lars Lannfelt, Professor, Uppsala University, Sweden

10.30 COFFEE BREAK AND POSTER VIEWING

10.50 – 12.30 GENETICS AND IMMUNOLOGICAL ASPECTS IN PSYCHIATRY  

Moderator: Sophie Erhardt (Stockholm, Sweden)

Diagnosis and treatment of maladaptive immunological responses presenting with psychiatric phenotypes

• Janet Cunningham, Assoc. Prof., Uppsala University, Sweden

Treatment of minocycline and schizophrenia

• Carl Sellgren. MD, PhD, Karolinska Institutet, Sweden

Shared genetic risk across psychiatric and neurological disorders”.

• Olav Bjerkehagen Smeland, MD, PhD, University of Oslo, Norway)

Understanding the genetics of psychiatric disorders in the era of GWAS

• Sarah Bergen, PhD, Karolinska Institutet, Sweden

Lithium - pharmacokinetics, genetics and nanofluidics

• Martin Schalling, Professor, Karolinska Institutet, Sweden

12.30 – 13.30 LUNCH AND POSTER VIEWING

13.30 – 15.00 SCNP YOUNG SCIENTIST SYMPOSIUM

Moderator: Gregers Wegener, Professor, Aarhus University, Denmark

1. Risk factors for developing disorder and impulse-control disorders under dopaminergic medication
   Mirjan Wolfschlag
   Faculty of Medicine, Dept of Clinical Sciences Lund, Lund University, Psychiatry, Lund, Sweden, & Malmö-Trelleborg Addiction Center, Competence Center Addiction, Region Skåne, Malmö, Sweden
2. Initiation of antidepressant treatment and the risk of manic episodes in children and adolescents with unipolar depression
   Suvi Virtanen^,
   Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Sweden
3. Quasi-tenacious depression (QTD) as an alternative framework to treatment-resistant depression (TRD)
   Shokouh Arjmand
   Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
4. Cardiovascular proteins are elevated in first-episode psychosis patiens compared to healty controls
   Anna Kristina Malmqvist-Bahrami
   Karolinska institutet, Sweden
5. Accumbal Cholinergic signaling regulates ethanol intake in the rat
   Anna Loftén
   Addiction Biology Unit, Institution of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Sweden & Beroendekliniken, Shalgrenska University Hospital, Gothenburg, Sweden
6. Kynurenic acid promotes activity-dependent synaptic pruning and associates with genetic risk variance for schizophrenia
   Funda Orhan
   Karolinska Institutet, Sweden

15:00 – 15:30 COFFEE BREAK AND POSTER VIEWING

15.30 – 16.30 Treatment of depressive disorders (20 min + 10min)

Moderator: Ingrid Dieset, MD, PhD, Oslo University, Norway

Management of treatment-resistant depression: old ideas (& new)

• Elias Eriksson, Professor, Gothenburg University, Sweden

Real-world effectiveness of pharmacotherapies in psychotic depression

• Heidi Taipale, PhD, Karolinska Institutet, Sweden

16.30 – POSTER VIEWING (REFRESHMENTS)

18.30 – Buses leave KI for dinner

VENUE: Eva and Georg Klein Lecture Hall, Biomedicum, KI

08.30 - 9.10 KEYNOTE LECTURE

Moderator: Bo Söderpalm, Professor, Gothenburg University, Sweden

Cannabis — The Good, The Bad and the Ugly in Relation to Psychiatric Disorders

• Yasmin Hurd, Professor, Icahn School of Medicine at Mount Sinai, USA

09.10 – 9.55 In Memorian of Torgny H. Svensson

Moderator: Sophie Erhardt, Professor, Karolinska Institutet, Sweden)

Professor Torgny H. Svensson 1945-2020

• Göran Engberg, Professor, Karolinska Institutet, Sweden

The Torgny H. Svensson Award Lecture

Rethinking the mechanism of antidepressants (on TRKB)

• Plinio Casarotto, PhD

9.55 – 10.20 Honorary member lecture

Psychedelics in depression – opportunities and challenges

• Prof. Ole Andreassen, Professor Oslo University, Norway

10.20 – 10.45 COFFEE BREAK AND POSTER VIEWING

10.45 – 12.15 UPDATE ON NEW DRUGS

Moderator: Henry Karlsson, Assoc. Prof., University of Turku, Finland

Targeting Brain Kynurenic Acid for Cognitive Improvement

• Robert Schwarcz, Professor, University of Maryland School of Medicine, USA

Ulotaront: A Novel TAAR1 Agonist in Development for the Treatment of Schizophrenia

• Nicholas DeMartinis, MD, VP Head of Global Clinical Research Psychiatry, Sunovion Pharmaceuticals Inc.

Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder

• Susanne Bejerot, Professor, Örebro University, Sweden

12.15 - 13:15 LUNCH AND POSTER VIEWING

13.15 – 14.00 KEYNOTE LECTURE

Moderator: Bo Söderpalm, Professor, Gothenburg University, Sweden

Treatment Strategies for ADHD and Co-occurring Substance Use/Use Disorders

• Frances Levin, Professor, Columbia University, USA

14.00 -14.20 COFFEE BREAK AND POSTER VIEWING

14.20 – 16.00 Addiction, Suicide and ADHD

Moderator: Carl Björkholm, PhD, Janssen Pharmaceuticals, Sweden

Suicide prevention- how to turn the tide?

• Merete Nordentoft, Professor, University of Copenhagen, Denmark

Neuromodulation of subjective experience

• Siri Leknes, Professor, University of Oslo, Norway)

Role of Cognition in Alcohol Use Disorders

• Nitya Jayaram Lindström, PhD, Karolinska Institutet, Sweden

Gut-brain axis and addictive disorders

• Elisabet Jerlhag Holm, Professor, Gothenburg University, Sweden

Prevalence and pattern of intravenous use of methylphenidate in Iceland

• Gudrun Bjarnadottir, PhD, Landspitali University Hospital, Iceland

16:00 CONCLUSION OF MEETING

Sophie Erhardt & Bo Söderpalm